{"title": "Epidemic doubling time of the COVID-19 epidemic by Chinese province", "doi": "10.1101/2020.02.05.20020750", "citation_id": "2020.02.05.20020750v4", "date": "2020-02-28", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.02.05.20020750", "abstract": "<p>COVID-19 epidemic doubling time by Chinese province was increasing from January 20 through February 9, 2020. Yet, the harmonic mean doubling time was relatively short, ranging from 1.4 (Hunan, 95% CI, 1.2-2.0) to 3.0 (Xinjiang, 95% CI, 2.0-4.9) days, with an estimate of 2.5 days (95% CI, 2.4-2.7) for Hubei.</p>", "twitter_description": "COVID-19 epidemic doubling time by Chinese province was increasing from January 20 through February 9, 2020. Yet, the harmonic mean doubling time was relatively short, ranging from 1.4 (Hunan, 95% CI, 1.2-2.0) to 3.0 (Xinjiang, 95% CI, 2.0-4.9) days, with an estimate of 2.5 days (95% CI, 2.4-2.7) for Hubei.\n\n### Competing Interest Statement\n\nThe authors have declared no competing interest.\n\n### Funding Statement\n\nGC acknowledges support from NSF grant 1414374 as part of the joint NSF-NIH-USDA Ecology and Evolution of Infectious Diseases program. ICHF acknowledges salary support from the National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention (19IPA1908208). This article is not part of ICHF\u0092s CDC-sponsored projects.\n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nAll data analyzed is publicly available, aggregated, data. The data is provided in Table S1 in Technical Appendix 1.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.05.20020750v4.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.02.05.20020750v4", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.02.05.20020750v4.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/02/28/2020.02.05.20020750.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.02.05.20020750v4", "access_rights": "restricted", "authors": ["Kamalich Muniz-Rodriguez", "Gerardo Chowell", "Chi-Hin Cheung", "Dongyu Jia", "Po-Ying Lai", "Yiseul Lee", "Manyun Liu", "Sylvia K. Ofori", "Kimberlyn M. Roosa", "Lone Simonsen", "Cecile G. Viboud", "Isaac Chun-Hai Fung"]}